Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | MicrobiomeTrials← Back to trialsNCT06407232
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2024-08-08Est. Completion: 2027-08
Enrollment target: 90 participants Locations- UW Hospital and Clinics, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Cytomegalovirus Infections
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing …
Houston, United StatesEst. completion Feb 28, 2027
EBVHSVVZVHPVCMV
Background:
* Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore t…
Bethesda, United States
Recruiting
Cytomegalovirus (CMV)Inflammatory Bowel Disease (IBD)
Observational, single-center, non-pharmacological, prospective study of adult patients affected by Inflammatory Bowel Di…
Bologna, ItalyEst. completion Dec 31, 2026